ARTICLE | Company News
Vical deal
May 8, 1995 7:00 AM UTC
Merck & Co. paid VICL $3 million upon exercising its remaining three options to license the San Diego company's naked DNA vaccine technology for development of vaccines for hepatitis B, herpes simplex...